Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
146 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diarrhea - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea - Pipeline Review, H2 2017, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape. Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diarrhea - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 10, 2, 1, 21 and 4 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 4 molecules, respectively. Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Diarrhea - Overview 7 Diarrhea - Therapeutics Development 8 Pipeline Overview 8 Pipeline by Companies 9 Pipeline by Universities/Institutes 13 Products under Development by Companies 14 Products under Development by Universities/Institutes 17 Diarrhea - Therapeutics Assessment 18 Assessment by Target 18 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Diarrhea - Companies Involved in Therapeutics Development 27 A. Menarini Industrie Farmaceutiche Riunite Srl 27 Actelion Ltd 27 Aegis Therapeutics LLC 28 Akthelia Pharmaceuticals Ltd 28 Albireo Pharma Inc 29 Allergan Plc 29 Anatara Lifesciences Limited 30 Ardelyx Inc 30 Assembly Biosciences Inc 31 AzurRx BioPharma Inc 31 Bharat Biotech International Ltd 32 Cosmo Pharmaceuticals NV 32 DiscoveryBiomed Inc 33 GP Pharm SA 33 Miyarisan Pharmaceutical Company Ltd 34 Mucosis BV 34 Napo Pharmaceuticals Inc 35 Nippon Shinyaku Co Ltd 35 Novartis AG 36 Pfizer Inc 36 Prokarium Ltd 37 Rebiotix Inc 37 Recce Ltd 38 RedHill Biopharma Ltd 38 RxBio Inc 39 Scandinavian Biopharma Holding AB 39 Sigmoid Pharma Ltd 40 Summit Therapeutics Plc 40 Synthetic Biologics Inc 41 Syntiron LLC 41 Tasly Pharmaceutical Group Co Ltd 42 Wuhan Institute of Biological Products Co Ltd 42 Diarrhea - Drug Profiles 43 ABIM-101 - Drug Profile 43 AKT-10081 - Drug Profile 44 ASP-7147 - Drug Profile 45 AZX-1101 - Drug Profile 46 Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile 47 cadazolid - Drug Profile 48 Campylobacter jejuni [strain CPS81-176] vaccine - Drug Profile 50 CBM-588 - Drug Profile 52 cholestyramine - Drug Profile 54 crofelemer DR - Drug Profile 56 Drugs for Irritable Bowel Syndrome with Diarrhea - Drug Profile 60 Escherichia coli vaccine - Drug Profile 61 ETEC vaccine - Drug Profile 62 ETEC vaccine - Drug Profile 63 Etvax - Drug Profile 64 GXG-8 - Drug Profile 66 ibodutant - Drug Profile 67 IMSUTMR-1501 - Drug Profile 68 infectious diarrhea [serotype H11] vaccine - Drug Profile 69 LJN-452 - Drug Profile 70 octreotide acetate - Drug Profile 71 octreotide acetate MAR - Drug Profile 72 ondansetron hydrochloride CR - Drug Profile 73 ORP-101 - Drug Profile 80 Peptide to Activate NHE-3 for Diarrhea - Drug Profile 81 PF-06425090 - Drug Profile 82 prulifloxacin - Drug Profile 84 PZ-7475 - Drug Profile 86 RBX-2660 - Drug Profile 87 RDX-023 - Drug Profile 91 RDX-98940 - Drug Profile 92 RECCE-355 - Drug Profile 93 Recombinant Enzyme for Diarrhea - Drug Profile 94 ribaxamase - Drug Profile 95 ridinilazole - Drug Profile 101 rifamycin CR - Drug Profile 108 Rotavac-5C - Drug Profile 111 rotavirus [serotypes G1, G2, G3, G4, G8, G9] (hexavalent) vaccine - Drug Profile 112 Rx-100 - Drug Profile 113 Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile 115 Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 116 Small Molecules to Inhibit Beta-Glucuronidase for Chemotherapy Induced Diarrhea - Drug Profile 117 SYN-006 - Drug Profile 118 SYN-007 - Drug Profile 119 thuricin CD - Drug Profile 120 Typhetec - Drug Profile 121 Vaccine 1 for Diarrhea - Drug Profile 122 Vaccine 2 for Diarrhea - Drug Profile 123 Vaccine for Traveler's Diarrhea - Drug Profile 124 Vaccine for Traveler's Diarrhea - Drug Profile 125 Yersinia pestis vaccine - Drug Profile 126 Diarrhea - Dormant Projects 127 Diarrhea - Discontinued Products 130 Diarrhea - Product Development Milestones 131 Featured News & Press Releases 131 Appendix 141 Methodology 141 Coverage 141 Secondary Research 141 Primary Research 141 Expert Panel Validation 141 Contact Us 141 Disclaimer 142
List of Tables
Number of Products under Development for Diarrhea, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Diarrhea - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2017 Diarrhea - Pipeline by Actelion Ltd, H2 2017 Diarrhea - Pipeline by Aegis Therapeutics LLC, H2 2017 Diarrhea - Pipeline by Akthelia Pharmaceuticals Ltd, H2 2017 Diarrhea - Pipeline by Albireo Pharma Inc, H2 2017 Diarrhea - Pipeline by Allergan Plc, H2 2017 Diarrhea - Pipeline by Anatara Lifesciences Limited, H2 2017 Diarrhea - Pipeline by Ardelyx Inc, H2 2017 Diarrhea - Pipeline by Assembly Biosciences Inc, H2 2017 Diarrhea - Pipeline by AzurRx BioPharma Inc, H2 2017 Diarrhea - Pipeline by Bharat Biotech International Ltd, H2 2017 Diarrhea - Pipeline by Cosmo Pharmaceuticals NV, H2 2017 Diarrhea - Pipeline by DiscoveryBiomed Inc, H2 2017 Diarrhea - Pipeline by GP Pharm SA, H2 2017 Diarrhea - Pipeline by Miyarisan Pharmaceutical Company Ltd, H2 2017 Diarrhea - Pipeline by Mucosis BV, H2 2017 Diarrhea - Pipeline by Napo Pharmaceuticals Inc, H2 2017 Diarrhea - Pipeline by Nippon Shinyaku Co Ltd, H2 2017 Diarrhea - Pipeline by Novartis AG, H2 2017 Diarrhea - Pipeline by Pfizer Inc, H2 2017 Diarrhea - Pipeline by Prokarium Ltd, H2 2017 Diarrhea - Pipeline by Rebiotix Inc, H2 2017 Diarrhea - Pipeline by Recce Ltd, H2 2017 Diarrhea - Pipeline by RedHill Biopharma Ltd, H2 2017 Diarrhea - Pipeline by RxBio Inc, H2 2017 Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H2 2017 Diarrhea - Pipeline by Sigmoid Pharma Ltd, H2 2017 Diarrhea - Pipeline by Summit Therapeutics Plc, H2 2017 Diarrhea - Pipeline by Synthetic Biologics Inc, H2 2017 Diarrhea - Pipeline by Syntiron LLC, H2 2017 Diarrhea - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017 Diarrhea - Pipeline by Wuhan Institute of Biological Products Co Ltd, H2 2017 Diarrhea - Dormant Projects, H2 2017 Diarrhea - Dormant Projects, H2 2017 (Contd..1), H2 2017 Diarrhea - Dormant Projects, H2 2017 (Contd..2), H2 2017 Diarrhea - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
